These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21817194)

  • 1. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
    McKinnon JE; Delgado R; Pulido F; Shao W; Arribas JR; Mellors JW
    Antivir Ther; 2011; 16(5):725-32. PubMed ID: 21817194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
    Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
    Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
    AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
    Sutherland KA; Parry CM; McCormick A; Kapaata A; Lyagoba F; Kaleebu P; Gilks CF; Goodall R; Spyer M; Kityo C; Pillay D; Gupta RK;
    PLoS One; 2015; 10(9):e0137834. PubMed ID: 26382239
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
    mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
    Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
    AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
    Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
    J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
    Ghosn J; Delaugerre C; Flandre P; Galimand J; Cohen-Codar I; Raffi F; Delfraissy JF; Rouzioux C; Chaix ML
    PLoS One; 2011; 6(9):e24798. PubMed ID: 21949754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
    Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
    Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
    Blanch-Lombarte O; Santos JR; Peña R; Jiménez-Moyano E; Clotet B; Paredes R; Prado JG
    J Antimicrob Chemother; 2020 Sep; 75(9):2535-2546. PubMed ID: 32556165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
    Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
    J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
    Kletenkov K; Hoffmann D; Böni J; Yerly S; Aubert V; Schöni-Affolter F; Struck D; Verheyen J; Klimkait T;
    J Antimicrob Chemother; 2017 Mar; 72(3):866-875. PubMed ID: 27999036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
    Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
    Taylor BS; Hunt G; Abrams EJ; Coovadia A; Meyers T; Sherman G; Strehlau R; Morris L; Kuhn L
    AIDS Res Hum Retroviruses; 2011 Sep; 27(9):945-56. PubMed ID: 21345162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
    Larrouy L; Chazallon C; Landman R; Capitant C; Peytavin G; Collin G; Charpentier C; Storto A; Pialoux G; Katlama C; Girard PM; Yeni P; Aboulker JP; Brun-Vezinet F; Descamps D;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2910-9. PubMed ID: 20439606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.
    González de Requena D; Gallego O; Valer L; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):275-8. PubMed ID: 15117450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.